title: A higher degree of criticism about the effectiveness of bosentan for digital ulcers in scleroderma patients, as for interstitial disease, is also necessary: comment on the article by Seibold et al.
authors.forename: Markus
authors.initials: M
authors.lastname: Bredemeier
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use*; D000077300:Bosentan; D016232:Endothelins / Q000502:physiology; D005385:Fingers; D006801:Humans; D012595:Scleroderma, Systemic / Q000188:drug therapy* / Q000503:physiopathology; D012883:Skin Ulcer / Q000503:physiopathology / Q000517:prevention & control*; D013449:Sulfonamides / Q000627:therapeutic use*
chemical_list: D000959:Antihypertensive Agents; D016232:Endothelins; D013449:Sulfonamides; D000077300:Bosentan